Yeast bioassay for identification of inositol depleting compounds

References

• Azab AN, He Q, Ju S, Li G, Greenberg ML. Glycogen synthase kinase-3 is required for optimal de novo synthesis of inositol. Mol Microbiol 2007; 63: 1248–1258
   PubMed Web of Science ®Google Scholar
• Baillie T, Sheffels PR. Valproic acid: Chemistry and biotransformation. Antiepileptic drugs. Chapter 474th ed, RH Levy, RH Mattson, BS Meldrum. Raven Press, New York 1995; 589–604
   Google Scholar
• Barnett JE, Brice RE, Corina DL. A colorimetric determination of inositol monophosphates as an assay for D-glucose 6-phosphate-1L-myoinositol 1-phosphate cyclase. Biochem J 1970; 119: 183–186
   PubMedGoogle Scholar
• Belmaker RH. Bipolar disorder. New Engl J Med 2004; 351: 476–486
   PubMed Web of Science ®Google Scholar
• Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989; 341: 197–205
   PubMed Web of Science ®Google Scholar
• Chapman AG, Croucher MJ, Meldrum BS. Anticonvulsant activity of intracerebroventricularly administered valproate and valproate analogues. A dose-dependent correlation with changes in brain aspartate and GABA levels in DBA/2 mice. Biochem Pharmacol 1984; 33: 1459–1463
   PubMedGoogle Scholar
• Colina AR, Young D. Raf60, a novel component of the Rpd3 histone deacetylase complex required for Rpd3 activity in Saccharomyces cerevisiae. J Biol Chem 2005; 280: 42552–42556
   PubMedGoogle Scholar
• Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332–372
   PubMed Web of Science ®Google Scholar
• De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158–1164
   PubMed Web of Science ®Google Scholar
• Eickholt BJ, Towers GJ, Ryves WJ, Eikel D, Adley K, Ylinen LM, et al. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol Pharmacol 2005; 67: 1426–1433
   PubMedGoogle Scholar
• Elion EA, Warner JR. The major promoter element of rRNA transcription in yeast lies 2 kb upstream. Cell 1984; 39: 663–673
   PubMed Web of Science ®Google Scholar
• Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969–6978
   PubMed Web of Science ®Google Scholar
• Gross-Isseroff R, Salama D, Israeli M, Biegon A. Autoradiographic analysis of [3H]ketanserin binding in the human brain postmortem: effect of suicide. Brain Res 1990; 507: 208–215
   PubMedGoogle Scholar
• Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980; 255: 10896–10901
   PubMed Web of Science ®Google Scholar
• Hirsch JP, Henry SA. Expression of the Saccharomyces cerevisiae inositol-1-phosphate synthase (INO1) gene is regulated by factors that affect phospholipid synthesis. Mol Cell Biol 1986; 6: 3320–3328
   PubMedGoogle Scholar
• Isojarvi JI, Lofgren E, Juntunen KS, Pakarinen AJ, Paivansalo M, Rautakorpi I, et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 2004; 62: 247–253
   PubMed Web of Science ®Google Scholar
• Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9: 199–216
   PubMedGoogle Scholar
• Ju S, Shaltiel G, Shamir A, Agam G, Greenberg ML. Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J Biol Chem 2004; 279: 21759–21765
   PubMed Web of Science ®Google Scholar
• Kadosh D, Struhl K. Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell 1997; 89: 365–371
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Klig LS, Henry SA. Isolation of the yeast INO1 gene: located on an autonomously replicating plasmid, the gene is fully regulated. Proc Natl Acad Sci USA 1984; 81: 3816–3820
   PubMedGoogle Scholar
• Kumar S, Wong H, Yeung SA, Riggs KW, Abbott FS, Rurak DW. Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination. Drug Metab Dispos 2000; 28: 857–864
   PubMed Web of Science ®Google Scholar
• Maslanski JA, Busa W.B. Methods in inositide research. Raven Press, New York 1990; 113–126
   Google Scholar
• Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M. Pharmacodynamic properties of N-dipropylacetic acid. Therapie 1963; 18: 435–438
   PubMedGoogle Scholar
• Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002; 59: 115–123
   PubMed Web of Science ®Google Scholar
• Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, Wood JR, Legro RS, Strauss JF 3rd, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145: 799–808
   PubMed Web of Science ®Google Scholar
• Novak JE, Turner RS, Agranoff BW, Fisher SK. Differentiated human NT2-N neurons possess a high intracellular content of myo-inositol. J Neurochem 1999; 72: 1431–1440
   PubMedGoogle Scholar
• Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734–36741
   PubMed Web of Science ®Google Scholar
• Robert E, Francannet C. Comments on “Teratogen update on lithium” by J. Warkany. Teratology 1990; 42: 205
   PubMedGoogle Scholar
• Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; 2: 937
   PubMed Web of Science ®Google Scholar
• Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, et al. Valproate decreases inositol biosynthesis. Biol Psychiatry 2004; 56: 868–874
   PubMed Web of Science ®Google Scholar
• Shi Y, Vaden DL, Ju S, Ding D, Geiger JH, Greenberg ML. Genetic perturbation of glycolysis results in inhibition of de novo inositol biosynthesis. J Biol Chem 2005; 280: 41805–41810
   PubMedGoogle Scholar
• Stein AJ, Geiger JH. Structural studies of MIP synthase. Acta Crystallogr D Biol Crystallogr 2000; 56: 348–350, Pt 3
   PubMedGoogle Scholar
• Vaden DL, Ding D, Peterson B, Greenberg ML. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem 2001; 276: 15466–15471
   PubMed Web of Science ®Google Scholar
• Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, et al. Affective disorders in five United States communities. Psychol Med 1988; 18: 141–153
   PubMed Web of Science ®Google Scholar
• Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292–295
   PubMed Web of Science ®Google Scholar
• Wong YH, Kalmbach SJ, Hartman BK, Sherman WR. Immunohistochemical staining and enzyme activity measurements show myoinositol-1-phosphate synthase to be localized in the vasculature of brain. J Neurochem 1987; 48: 1434–1442
   PubMed Web of Science ®Google Scholar